{"protocolSection":{"identificationModule":{"nctId":"NCT06476704","orgStudyIdInfo":{"id":"2020-016"},"secondaryIdInfos":[{"id":"2024-515668-30-00","type":"CTIS"}],"organization":{"fullName":"Institut de cancérologie Strasbourg Europe","class":"OTHER"},"briefTitle":"Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","officialTitle":"Phase 2 Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas","acronym":"PRACTISS"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-01-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2030-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2030-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-21","studyFirstSubmitQcDate":"2024-06-21","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-26","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Institut de cancérologie Strasbourg Europe","class":"OTHER"},"collaborators":[{"name":"LEAF4Life, Inc.","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is phase II randomized, multicenter study of treatment with liposomal trasncrocetin (L-TC) and preoperative hypofractionated radiotherapy in patients who were aged 18 years or older with documented localised or locally advanced soft-tissue sarcoma of the extremity.","detailedDescription":"Eligible patients will be randomly assigned 2:1 to receive a preoperative hypofractionated radiotherapy alone (Arm A) or L-TC with preoperative hypofractionated radiotherapy (HFRT) (Arm B).\n\nAll eligible patients will be administered L-TC at a dose of 300 mg as an IV perfusion, daily and the radiation session will be between 30 min and 1h30 after the end of the perfusion.\n\nThe experimental treatment, L-TC, is a liposomal formulation of trans crocetin developed by LEAF4Life, Inc.\n\nControl group will receive HFRT alone."},"conditionsModule":{"conditions":["Sarcoma"],"keywords":["hypofractionated radiotherapy","soft tissue sarcoma","hypoxia","liposomal transcrocetin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":42,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Hypofractionated radiotherapy + Liposomal Transcorcetin (L-TC)","type":"EXPERIMENTAL","interventionNames":["Drug: Administration of L-TC"]},{"label":"Hypofractionated radiotherapy alone","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: HFRT alone"]}],"interventions":[{"type":"DRUG","name":"Administration of L-TC","description":"Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session","armGroupLabels":["Hypofractionated radiotherapy + Liposomal Transcorcetin (L-TC)"]},{"type":"RADIATION","name":"HFRT alone","description":"HFRT : 30 Gy in 5 fractions of 6 Gy.\n\n1 fraction per day, 5 days per week.","armGroupLabels":["Hypofractionated radiotherapy alone"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Evaluation of the efficacy of the L-TC treatment in combination with preoperative hypofractionated radiotherapy.","description":"Pathological complete response rate (pCR): defined as the presence of \\< 10% residual malignant viable cells. Wardelmann et al. proposed pathological evaluation criteria","timeFrame":"At surgery"}],"secondaryOutcomes":[{"measure":"Evaluation of the acute tolerance o f L-TC","description":"Treatment-related adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","timeFrame":"until 5 weeks"},{"measure":"Evaluation of the late tolerance o f L-TC","description":"Treatment-related adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","timeFrame":"tourough study until 5 years"},{"measure":"Evaluation of the necrosis","description":"Median percentage pathologic necrosis on histologic examination","timeFrame":"At surgery"},{"measure":"Evaluation of the radiological response","description":"Proportion of patients with a complete or partial radiological response (according to RECIST 1.1: Evaluated on MRI","timeFrame":"until surgery"},{"measure":"Proportion of patients with R0 resection","description":"Number of patients with R0 resection on the number of enrolled patients","timeFrame":"At surgery"},{"measure":"Evaluation of the Overall Survival (OS)","description":"OS will be defined as the length of time from the date of diagnostic by biopsy to the date of death","timeFrame":"Until 5 years"},{"measure":"Evaluation of the Progression-Free Survival (PFS)","description":"PFS will be defined as the length of time from the date of diagnostic by biopsy to the date of relapse","timeFrame":"Until 5 years"},{"measure":"Evaluation of the Quality of Life (QoL)","description":"Use of the European Organisation for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire (QLQ-C30)","timeFrame":"Until 5 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18 years\n* Localised or locally advanced soft tissue sarcoma of extremity proven by biopsy whatever its histological grade.\n* Pathological expert proof-reading in reference centre\n* Candidate to radiotherapy + surgery as decided in a multidisciplinary tumour board, in reference centre (European Society for Medical Oncology (ESMO) guideline 2021)\n* R0 surgery is feasible, in reference centres.\n* Pre-biopsy MRI available\n* Performance status of 0-2 and life expectancy of at least 6 months\n* Patients should have normal liver function as defined by ALT, AST and alkaline phosphate less than 3 ULN for the institution.\n* Patient must have platelet count above \\>100,000 cells/mm3, hemoglobin \\> 8 g/dL and an absolute neutrophil count (ANC) of \\> 1000 cells/mm3.\n* Patients should have normal renal function as defined by creatinine clearance of 50 ml/min or higher.\n* Signed informed consent from the patient must be obtained prior to any procedures\n\nExclusion Criteria:\n\n* Woman who is pregnant or breastfeeding\n* Soft tissue sarcoma developed in irradiated area.\n* Patients with myxoid liposarcoma, embryonal or alveolar rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, angiosarcoma, primitive neuroectodermal tumor, desmoid-type fibromatosis, or dermatofibrosarcoma protuberans\n* Patient with metastatic disease, other concomitant cancer or history of cancer treated and controlled within the previous 3 years.\n* Patient who has a known hypersensitivity to crocetins, L-TC or any of its excipients\n* Patient who cannot or understand French language\n* Patient under legal protection (curatorship, guardianship)\n* Patient without French National Health insurance","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Manon VOEGELIN","role":"CONTACT","phone":"368339523","phoneExt":"+33","email":"promotion-rc@icans.eu"}],"overallOfficials":[{"name":"Isabelle CHAMBRELANT, MD","affiliation":"Institut de cancérologie Strasbourg Europe","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Georges NOEL, MD, PhD","affiliation":"Institut de cancérologie Strasbourg Europe","role":"STUDY_CHAIR"}],"locations":[{"facility":"Institut de cancérologie Strasbourg Europe","city":"Strasbourg","zip":"67033","country":"France","contacts":[{"name":"Manon VOEGELIN","role":"CONTACT","phone":"368339523","phoneExt":"+33","email":"promotion-rc@icans.eu"}],"geoPoint":{"lat":48.58392,"lon":7.74553}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000012509","term":"Sarcoma"}],"ancestors":[{"id":"D000018204","term":"Neoplasms, Connective and Soft Tissue"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"}],"browseLeaves":[{"id":"M15327","name":"Sarcoma","asFound":"Sarcoma","relevance":"HIGH"},{"id":"M4185","name":"Hypoxia","relevance":"LOW"},{"id":"M20350","name":"Neoplasms, Connective and Soft Tissue","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"T5284","name":"Soft Tissue Sarcoma","asFound":"Soft Tissue Sarcoma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}